Best Immunotherapy Companies in Germany
The 50 best Immunotherapy companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CureVac.
- ResearchAndMarkets.com
- The Business Research Company
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | CureVac Developer of mRNA-based therapeutics against cancer and infectious diseases 55Patents top 20%Funding top 28%Moat top 29%Innovation top 32% All 11 signals ▾Patentstop 20% Fundingtop 28% Moattop 29% Innovationtop 32% Partnerstop 41% Markettop 43% Newstop 45% Talenttop 49% Techbottom 49% Globalbottom 46% Growthbottom 38% Patents: 1,737 patents matched (strict assignee match) · 461 filings since 2022 vs 745 in 2017-21 Funding: Raised $975M across 14 rounds · 14 rounds over 23 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $975M | 70 mo ago | 648 648 → 678 (+5%) | Florian Mulbe Co-Founder & CPO | 13 signals ▼50% M&A · Regulatory · Earnings | 1,728 patents Patents concentrated in health & consumer products | — |
| 2 | BioNTech Developer of immunotherapeutics for the treatment of cancer and other diseases 78Patents top 7%Innovation top 17%News top 26%Tech top 28% All 13 signals ▾Patentstop 7% Innovationtop 17% Newstop 26% Techtop 28% Globaltop 28% Fundingtop 29% Talenttop 29% Growthtop 33% Moattop 35% Producttop 39% Markettop 48% Partnersbottom 43% Fin. healthbottom 42% Patents: 2,228 patents matched (strict assignee match) · 1521 filings since 2022 vs 431 in 2017-21 Innovation: 2,228 patents (top 1% of patent-holders) · 1521 filings since 2022 vs 431 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $806M | 51 mo ago | 4,530 4,530 → 5,204 (+15%) | Christoph Huber Co-Founder & Managing Director | 20 signals ▼23% Leadership · Announcements · Earnings | 2,227 patents mRNA vaccine formulation and delivery, nucleic‑acid therapeutics, cancer immunotherapy antibodies | 1 partnership |
| 3 | MorphoSys Developer of antibodies for treating cancer | $770M | 69 mo ago | 732 | Andreas Pluckthun Co-Founder | — | 1,328 patents Therapeutic antibody engineering, formulation, and purification for CD38/CD19 targets | — |
| 4 | Immatics Developer of T -cell-based immunotherapies for the treatment of cancer 76Product top 14%Funding top 23%News top 23%Patents top 30% All 10 signals ▾Producttop 14% Fundingtop 23% Newstop 23% Patentstop 30% Techtop 31% Growthtop 32% Moattop 32% Innovationtop 39% Markettop 41% Globaltop 50% Product: 6 distinct product lines · Company stage: Public Funding: Raised $236M across 7 rounds · 7 rounds over 22 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 76/100 | $236M | 36 mo ago | 198 | — | 9 signals ▲125% Leadership · Funding · Earnings | 43 patents TCR-engineered T‑cell therapies and peptide‑MHC based immune cell selection platforms | — |
| 5 | Tubulis Technologies Developer of antibody-drug conjugates for the treatment of cancer 60News top 15%Funding top 18%Growth top 20%Patents top 27% All 10 signals ▾Newstop 15% Fundingtop 18% Growthtop 20% Patentstop 27% Moattop 28% Innovationtop 35% Talenttop 50% Marketbottom 42% Globalbottom 42% Techbottom 32% News: 13 BI events in 12 mo (of 21 tracked, 3 types) · +333% YoY Funding: Raised $214M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $214M | 9 mo ago | 33 | Dominik Schumacher Co-Founder & CEO | 13 signals ▲333% M&A · Funding · Leadership | 70 patents Phosphorus(V)-based linkers for antibody-drug conjugates and phosphonamidate synthesis | — |
| 6 | Ganymed Pharmaceuticals Developer of antibody-based drugs for the treatment of solid cancers | $212M | 152 mo ago | 4 | — | — | 1,019 patents Targeted antibody therapeutics against claudin‑6 and claudin‑18.2 for oncology | — |
| 7 | T-Knife Developer of tumor-specific T cell receptor therapies for the treatment of cancer | $188M | 60 mo ago | 8 | Elisa Kieback Co-Founder & CEO | — | 20 patents Engineered T‑cell immunotherapy constructs: chimeric CD8/CD95 receptors and KRAS‑specific TCRs | 1 expansion |
| 8 | Glycotope Developer of Glyco-optimized antibodies and provider of contract research and manufacturing services. | $166M | 130 mo ago | 116 | Steffen Goletz CEO | — | 492 patents Therapeutic antibodies and recombinant production of MUC1 and surfactant protein D. | — |
| 9 | iOmx Developer of checkpoint modulators for treating cancer | $120M | 58 mo ago | 33 33 → 53 (+61%) | — | — | — | — |
| 10 | Affimed Therapeutics Developer of antibody therapeutic solutions for cancer treatment | $90M | 139 mo ago | 197 | Adi Hoess CEO | — | 56 patents Engineered multivalent antibody fragments targeting CD16 and EGFRvIII for immune cell engagement | — |
| 11 | Medigene Developer of T cell immunotherapies for haematological malignancies 62Product top 14%Patents top 32%Funding top 34%Innovation top 37% All 12 signals ▾Producttop 14% Patentstop 32% Fundingtop 34% Innovationtop 37% Fin. healthtop 38% Growthtop 40% Moattop 41% Markettop 42% Partnerstop 45% Techbottom 44% Globalbottom 44% Newsbottom 26% Product: 5 distinct product lines · Company stage: Public Patents: 341 patents matched (strict assignee match) · 4 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $82M | 27 mo ago | 114 | — | — | 328 patents Liposomal drug delivery systems and immunomodulatory heterocyclic compounds for cancer vaccines | — |
| 12 | Apogenix Developer of novel protein therapeutics for the treatment of cancer and inflammatory diseases | $72M | 55 mo ago | 57 | — | — | 369 patents Engineered multi-specific protein agonists for immune checkpoint modulation and cancer therapy | — |
| 13 | SuppreMol Developer of therapeutics for the treatment of autoimmune diseases | $71M | 158 mo ago | 50 | Jose Almeida CEO | — | 185 patents Therapeutic antibodies and soluble Fc receptor biologics for immune modulation | — |
| 14 | Topas Therapeutics Developer of nanoparticle-based therapeutics for immunology disorders | $69M | 60 mo ago | 14 14 → 21 (+50%) | — | — | 54 patents Targeted nanoparticle delivery systems for antigens and viral vectors in immunotherapy | — |
| 15 | InflaRx Developer of antibody therapeutics for inflammatory and immune diseases | $64M | 105 mo ago | 56 56 → 47 (-16%) | Renfeng Guo Co-Founder | 6 signals ▲500% Earnings · Announcements · Incorporation | 152 patents C5a complement receptor antagonists (small molecules and antibodies) for inflammatory disease therapy | — |
| 16 | U3 Pharma Antibody-based protein therapies primarily for cancer | $49M | 242 mo ago | — | Johannes Bange CEO | — | 214 patents HER3-targeted antibody‑drug conjugates and nucleic‑acid biomarker diagnostics | — |
| 17 | Affectis Developer of drugs for the treatment of neurodegenerative and neuroinflammatory diseases | $25M | 196 mo ago | — | Herbert Stadler Founder | — | — | — |
| 18 | T-CURX Developer of immune-based cancer treatments with T-cells 27Funding top 40%Moat top 45%Patents bottom 49%Talent bottom 49% All 6 signals ▾Fundingtop 40% Moattop 45% Patentsbottom 49% Talentbottom 49% Globalbottom 40% Innovationbottom 36% Funding: Raised $21.4M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $21M | 7 mo ago | — | Christian Sollner Founder | — | 5 patents Engineered immune cell production and advanced transposon-based gene delivery vectors. | — |
| 19 | Micromet Antibody-based therapies for the treatment of cancer | $10M | 214 mo ago | 15 | — | — | 354 patents Bispecific single-chain antibody engineering for targeted immunotherapy, especially CD19×CD3 therapeutics. | — |
| 20 | ImevaX Vaccines for chronic and nosocomical infections | $10M | 137 mo ago | 1 | — | — | 20 patents Therapeutic treatments targeting Helicobacter pylori infections | — |
| 21 | Mologen Vaccines and immunomodulators for the treatment of cancer and infectious diseases | $6M | 100 mo ago | 38 | — | — | 263 patents Synthetic immunostimulatory oligonucleotide therapeutics for HIV, cancer immunotherapy, and vaccine adjuvants | — |
| 22 | ActiTrexx Provider and developer of cellular therapy agents for stem cell transplantation patients | $4M | 65 mo ago | 11 | Andrea Tüttenberg Tuttenberg Co-Founder & CEO | — | — | — |
| 23 | VERAXA Developer of antibody therapeutics for cancer treatment | $3M | 85 mo ago | 36 | Edward A. Lemke Co-Founder | — | — | 1 partnership |
| 24 | Protectimmun Treatments for prevention and therapy of allergic and chronic inflammatory diseases | $2M | 183 mo ago | — | Otto Holst Co-Founder | — | 17 patents Therapeutic compositions and synthetic arabinogalactans for allergy and inflammatory disease treatment | — |
| 25 | T-Cell Europe Cell-based therapies for kidney transplants patients. | $2M | 170 mo ago | 2 | — | — | — | — |
| 26 | Lumobiotics Photoswitchable peptides for pancreatic cancer and prosthetic joint infections | $199K | 65 mo ago | — | Leo St Founder & COO | — | — | — |
Top 12 Immunotherapy companies in Germany
#1
Acquired · Munich, Bavaria · founded 2015 · 33 employees$214.1Mraised▾
Developer of antibody-drug conjugates for the treatment of cancer. The company has proprietary technology platforms which include the Tub-tag conjugation platform, P5 conjugation platform, and Topoisomerase-I inhibitor platform to develop antibody-drug conjugates for solid and hematological tumors. It offers TUB-040 for ovarian and non-small cell lung cancer. TUB-030, TUB-050, and TUB-060 for solid tumors.
- Oct 2025Series C$401M
- Mar 2024Series B$138.8M
- Aug 2022Grant (prize money)—
- May 2022Series B$63.1M
#2
Series A · Wurzburg, Bavaria · founded 2016$21.4Mraised▾
T-CURX is developing immune-based cancer treatments with T-cells. They are developing new generation UltraModularCAR T cells (transformative, chemotherapy-free treatment) for treating leukemia, lymphoma, breast cancer, and lung cancer. It's in phase I/II a clinical trial for safety and efficacy evaluation.
- Dec 2025Series A$20.8M
- Jan 2018Grant (prize money)$605.1K
#3
Public · Planegg, Bavaria · founded 1994 · 114 employees$81.9Mraised▾
Developer of T cell immunotherapies for haematological malignancies. Its product pipeline includes Dendritic cell vaccine for AML and prostate cancer, T cell specific antibodies for leukemia, and T cell receptor based therapy for different cancers.
- May 2024Post IPO$6.4M
- May 2018Post IPO$37.9M
- Jun 2012Post IPO$17.7M
- Mar 2004Post IPO$20M
#4
Public · Tubingen, Baden Wurttemberg · founded 2000 · 198 employees$236.4Mraised▾
Developer of T -cell-based immunotherapies for the treatment of cancer. The company has propriety platform XPRESIDENT is involved in identifying and validating antigens specific to cancer cells and subsequently develops adoptive cell therapies and bispecific TCRs for treating cancer. IMA101, using its proprietary ACTolog approach, which is T-cell products generated from peripheral blood cells with defined target selectivity.
- Jul 2023Post IPO$35M
- Aug 2020Post IPO—
- Oct 2017Series E$58M
- Jan 2016Grant (prize money)$1.4M
#5
Public · Mainz, Rhineland-Palatinate · founded 2008 · 4530 employees$806Mraised▾
Developer of immunotherapeutics for the treatment of cancer and other diseases. Its oncology drug pipeline contains several classes of drugs which include mRNA treatments, modified cell therapies, antibodies, and small molecule immunomodulators that have been optimised for distinct modes of action, high precision targeting, potency, and efficacy.
- Apr 2022Post IPO$150M
- Sep 2020Post IPO$444.8M
- Jun 2020Post IPO$250M
- Mar 2020Post IPO$133.3M
#6
Acquired · Tubingen, Baden Wurttemberg · founded 2000 · 648 employees$975.3Mraised▾
Developer of mRNA-based therapeutics against cancer and infectious diseases. It has developed RNAntibody to enable the expression of functional antibodies and antibody-like proteins from mRNA. The lead product includes CV9104, an investigational therapeutic vaccine to treat prostate cancer. The vaccine is injected into the skin to stimulate the body's immune system to destroy prostate cancer cells. The company's other product includes CV8102 for cutaneous myeloma and CV9202 used to treat patients with non-small cell lung cancer.
- Sep 2020Grant (prize money)$299M
- Jul 2020Series F$126M
- Jul 2020Series F$171M
- Jul 2020Conventional Debt$84.3M
#7
Acquired · Planegg, Bavaria · founded 1992 · 732 employees$770.1Mraised▾
Developer of antibodies for treating cancer. It is an integrated biopharma company engaged in the discovery, development, and commercialization of therapeutic antibodies for cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction, and inflammation. Their lead candidate is MOR208 for Diffuse large B cell lymphoma (DLBCL). The company's lead technologies include HuCAL (Human Combinatorial Antibody Library), and Ylanthia (the industry’s largest antibody Fab library which uses novel methods for in vitro generation of specific and human antibodies).
- Oct 2020Post IPO$383.8M
- Jan 2020Post IPO$150M
- Nov 2016Post IPO$123.9M
- Sep 2013Post IPO$112.3M
#8
Series B · Berlin, Berlin · founded 2018 · 8 employees$188.2Mraised▾
Tknife is a developer of tumor-specific T cell receptor therapies for the treatment of cancer. It is developing human TCRs to manufacture patient-derived T cell products targeting tumor-specific antigens for the treatment of various cancer. Its products help to detect cancer cells and initiate their elimination. The company has developed its proprietary transgenic mice (HuTCR mice) carrying the entire human TCRαβ gene loci. The T-cells of these HuTCR mice express a diverse human TCR repertoire. The company has also developed MAGE-A1 for the indication of myeloma.
- Aug 2021Series B$110M
- Aug 2020Series A$78.2M
#9
Series B · Munich, Bavaria · founded 2016 · 33 employees$120.1Mraised▾
Developer of checkpoint modulators for treating cancer. The company has developed a high-throughput siRNA-based screening approach that enables a comprehensive identification of ligands on human cancer cells that inhibit CTL-mediated tumor cell killing. The company has identified proprietary immune-oncology targets. The technology has been applied to tumor cells derived from breast cancer, pancreatic cancer, melanoma, and multiple myeloma.
- Oct 2021Series B$75.5M
- Sep 2016Series A$44.6M
#10
Series B · Hamburg, Hamburg · founded 2016 · 14 employees$68.5Mraised▾
Developer of nanoparticle-based therapeutics for immunology disorders. The company's pipeline drug candidates include TPM 203 for pemphigus Vulgaris, TPM 501/502 for celiac disease, and anti-drug immune response.
- Jul 2021Series B$21.3M
- Mar 2021Grant (prize money)$492.1K
- Oct 2020Series B$25.8M
- Apr 2020Grant (prize money)$290.8K
#11
Acquired · Mainz, Rhineland-Palatinate · founded 2001 · 4 employees$212.1Mraised▾
Developer of antibody-based drugs for the treatment of solid cancers. The company focuses on the development of a new class of cancer drugs including IMAB362, an antibody-drug candidate for the treatment of gastroesophageal cancer, and IMAB027, a monoclonal antibody to treat ovarian cancer. Its discovery programs are for breast cancer and solid tumors. It also develops Claudetect18.2, a CE marked in vitro diagnostic test to assess the expression levels of claudin-18.2 in the gastroesophageal, pancreatic, lung, and other solid tumors.
- Nov 2013Series E$57.3M
- Nov 2008Series D$82.8M
- Apr 2007Series C$45.5M
- Jul 2005Grant (prize money)$2M
#12
Series B · Heidelberg, Baden-wurttemberg · founded 2005 · 57 employees$72.3Mraised▾
Developer of novel protein therapeutics for the treatment of cancer and inflammatory diseases. The compound´s mechanism of action is either based on the targeted modulation of the programmed cell death or on the inhibition of tumour cell growth. The lead product is APG101 (fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody) is being developed for the treatment of Glioblastoma multiforme and myelodysplastic syndrome.
- Dec 2021Series B$29.4M
- Apr 2008Series B$42.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in Germany
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,045 Germany-affiliated papers.
- Heidelberg University290
- German Cancer Research Center198
- Charité - Universitätsmedizin Berlin148
- Ludwig-Maximilians-Universität München123
- University Hospital Heidelberg96
- Immune system13→187
- T cell2→64
- Cancer5→55
- Cancer research19→68
- Tumor microenvironment1→50
- Immune system18→298
- Oncology16→105
- Internal medicine24→101
- Cancer7→84
- Disease3→62
- Immune system1→99
- Disease1→52
- Cancer4→38
- Tumor microenvironment2→29
- Internal medicine4→31
Where immunology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in Germany
Germany immunology patent filing is cooling — 3,857 filings from 703 assignees (2016–2025), led by Immatics Biotechnologies, TRON Translationale Onkologie AN, Biontech SE; annual filings 201→144.
- Immatics Biotechnologies3119
- TRON Translationale Onkologie AN95
- Biontech SE87
- Biontech RNA Pharmaceuticals73
- Singh Harpreet54
- Weinschenk TONI53
- Fritsche JENS53
- Merck Patent45
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.